Phase 3Completed
Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients
Efficacy and Safety of Ilaprazole for GERD: A Randomized, Double-Blind, Esomeprazole-Controlled, Phase 3, Multicenter Trial in China
- Sponsor
- Livzon Pharmaceutical Group Inc. (Industry)
- Enrollment
- 550 enrolled
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- 10 mg ilaprazole; 40mg esomeprazole
- Ages
- adults, older adults
- Registry
- NCT02860624
Full record on ClinicalTrials.gov
From the registry
This study is designed to evaluate the efficacy and tolerability of ilaprazole relative to that of esomeprazole in healing erosive esophagitis and resolving accompanying symptoms of GERD.
Primary outcomes
- Changes in stage of the ulcer assessed by endoscopic(week 8) changes relative to baseline (week 0) levels.
History
Registered
Primary completion
Started